Keyphrases
Off-label Use
100%
Rituximab
71%
Tertiary Hospital
38%
Nephropathy
33%
Disease Activity
33%
Systemic Lupus Erythematosus
33%
Multicentric
33%
Extrarenal
33%
Partial Response
25%
Complete Response
25%
Partial Remission
24%
Focal Segmental Glomerulosclerosis
20%
Complete Remission
20%
Minimal Change Disease
20%
Membranoproliferative Glomerulonephritis
20%
No Response
18%
Thrombocytopenia
14%
Clinical Evidence
14%
Proteinuria
13%
Membranous Nephropathy
13%
Adult Patients
11%
Infusion Reaction
11%
Treatment Cycle
11%
Tolerability
11%
Electronic Medical Records
11%
Adverse Effects
9%
Joint Involvement
9%
Clinical Response
9%
Cutaneous Lupus Erythematosus
9%
Neurological Manifestations
9%
SLE Disease Activity Index (SLEDAI)
9%
KDIGO Guidelines
6%
CD19+
6%
Idiopathic Membranous Nephropathy
6%
Infectious Complications
6%
B Cells
6%
Pharmacology, Toxicology and Pharmaceutical Science
Off-Label Use
100%
Rituximab
77%
Retrospective Study
66%
Remission
42%
Kidney Disease
33%
Systemic Lupus Erythematosus
33%
Disease Activity
33%
Prospective Study
33%
Adverse Event
26%
Focal Glomerulosclerosis
16%
Membranous Glomerulonephritis
16%
Membranoproliferative Glomerulonephritis
16%
Disease
16%
Thrombocytopenia
14%
Prospective Cohort Study
11%
Clinical Trial
11%
Omalizumab
11%
Proteinuria
11%
Clostridium Botulinum Type A
11%
Tolerability
10%
Infusion Related Reaction
10%
Infectious Complication
5%